Skip to content

Study · Observational study · 2024

3 results

Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting.

Lv L, Brady BL, Xie L, Guevarra M, Turchin A

Primary care diabetes10 Jul 2024Cited by 12 (Europe PMC)

PMID38991896 (opens in a new tab)DOI10.1016/j.pcd.2024.06.013 (opens in a new tab)PepBankPUB-38991896
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

AimsTo investigate real-world treatment adherence and persistence in people with type 2 diabetes newly initiating oral semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), or a dipeptidyl peptidase-4 inhibitor (DPP-4i).MethodsThis retrospective cohort study used the Merative™ MarketScan® Commercial and Medicare databases. Index date was the first fill for the cohort medication. Adherence was defined as proportion of days covered (PDC) over the 12-month post-index period ('adherent' = ≥0.8). Persistence was number of days until discontinuation, based on a 45-day gap. Results were compared between cohorts using inverse probability treatment weighting.ResultsOral semaglutide (n=5485) and DPP-4i (n=4980) cohorts had similar percentages of people who were adherent (PDC ≥0.8; 41.6 % vs. 42.9 %; P = 0.182) and persistent for ≥9 months (45.0 % vs. 46.3 %; P = 0.185). The DPP-4i cohort used significantly more anti-diabetic medication (ADM) classes over the post-index period (mean±SD: 2.6±1.0 vs. 2.9±1.1, P < 0.001), with 23.2 % filling a GLP-1 RA in the post-period.ConclusionsAdherence and persistence were similar between cohorts. However, there are potential benefits to prescribing oral semaglutide over DPP-4is, including reduced need for additional ADM.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, adherence at 12 months was similar for new users of oral semaglutide and DPP-4 inhibitors (41.6% vs 42.9%).

    In plain wordsIn adults with type 2 diabetes, people starting oral semaglutide stuck to treatment about as well as people starting a DPP-4 inhibitor.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdherence (proportion of days covered 0.8 or higher)
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitor
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Adherent participants
    41.6%
    oral semaglutide
    Adherent participants
    42.9%
    DPP-4 inhibitor

    Source sentences

    Summary
    Oral semaglutide (n=5485) and DPP-4i (n=4980) cohorts had similar percentages of people who were adherent (PDC ≥0.8; 41.6 % vs. 42.9 %; P = 0.182)
    2 context sentences
    Summary · context
    To investigate real-world treatment adherence and persistence in people with type 2 diabetes newly initiating oral semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), or a dipeptidyl peptidase-4 inhibitor (DPP-4i).
    Summary · context
    This retrospective cohort study used the Merative™ MarketScan® Commercial and Medicare databases.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, persistence for at least 9 months was similar for new users of oral semaglutide and DPP-4 inhibitors (45.0% vs 46.3%).

    In plain wordsIn adults with type 2 diabetes, people starting oral semaglutide stayed on treatment about as long as people starting a DPP-4 inhibitor.

    Peptide
    Semaglutide
    Outcome
    No significant changePersistence for 9 months or longer
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitor
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Measurements

    Persistent participants
    45%
    oral semaglutide
    Persistent participants
    46.3%
    DPP-4 inhibitor

    Source sentences

    Summary
    Oral semaglutide (n=5485) and DPP-4i (n=4980) cohorts had similar percentages of people who were adherent (PDC ≥0.8; 41.6 % vs. 42.9 %; P = 0.182) and persistent for ≥9 months (45.0 % vs. 46.3 %; P = 0.185)
    2 context sentences
    Summary · context
    To investigate real-world treatment adherence and persistence in people with type 2 diabetes newly initiating oral semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), or a dipeptidyl peptidase-4 inhibitor (DPP-4i).
    Summary · context
    This retrospective cohort study used the Merative™ MarketScan® Commercial and Medicare databases.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, the oral semaglutide cohort used significantly fewer anti-diabetic medication classes than the DPP-4 inhibitor cohort.

    In plain wordsIn adults with type 2 diabetes, people on oral semaglutide needed fewer other diabetes medicine classes than people on a DPP-4 inhibitor.

    Peptide
    Semaglutide
    Outcome
    DecreaseNumber of anti-diabetic medication classes used after the index date
    Study

    n: not reported in source

    Comparator
    DPP-4 inhibitor
    Outcome group
    Patterns of use · Whole body
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    The DPP-4i cohort used significantly more anti-diabetic medication (ADM) classes over the post-index period (mean±SD: 2.6±1.0 vs. 2.9±1.1, P < 0.001), with 23.2 % filling a GLP-1 RA in the post-period.
    2 context sentences
    Summary · context
    To investigate real-world treatment adherence and persistence in people with type 2 diabetes newly initiating oral semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), or a dipeptidyl peptidase-4 inhibitor (DPP-4i).
    Summary · context
    This retrospective cohort study used the Merative™ MarketScan® Commercial and Medicare databases.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.